Technological Capabilities

Highly pure PEGs and mPEGs

Custom PEG specialties to meet the highest standards

Evonik offers a unique combination of skills essential to the development and manufacture of highly pure PEGs and mPEGs for pharmaceutical applications.

- Decades of experience handling ethylene oxide for the development and production of polyethylene glycol (PEG) for many industries.
- An integrated global network of sites in Germany and the USA.
- Decades of experience in API production.
- Professional and transparent project management for exclusive projects from one of the leading CMOs.
- Long track record in cGMP production at FDA-inspected production sites.

PEG and mPEG synthesis

Since 2017, Evonik has operated a specialized plant to produce PEGs for pharmaceutical applications in Hanau, Germany.

- In-house development
- High flexibility for new PEG specialties
- Kg scale production

Offering the whole value chain

Evonik offers the whole value chain for pegylated APIs:

- In-house production of PEG and mPEG specialties
- · Linker synthesis and activation
- API synthesis
- Conjugation

1. mPEG SYNTHESIS	2. mPEG ISOLATION	3. mPEG ACTIVATION	4. mPEG CONJUGATION
Different Grades	Analytical measurements	mPEG Functionalization	mPEG-API
2.000 Da	SEC	FG = Functional Group	e.g. mPEG-Insulin
5.000 Da	MALDI-TOF		
10.000 Da	NMR		
15.000 Da	HPLC		O Linker API
20.000 Da	IR		
30.000 Da	Karl-Fischer		
-0(O)OH			



Activation and conjugation

- Activation and linker synthesis under cGMP at Evonik sites in Germany and the USA.
- Conjugation development in our conjugation lab in Hanau, Germany.
- Further PEGylation development and manufacturing capabilities available at Birmingham, USA (including fill & finish).

PEGs and mPEGs for pharmaceutical applications

Large variety of PEG and mPEG specialties meeting the highest quality requirements:


- Polydispersity (Mw/Mn): ≤ 1.05
- Diol content (mPEG): < 1.0%
- Average molecular weight: +/- 5%

Complete analytical setup

Our facilities offer a complete analytical setup for PEGs and mPEGs. This includes the following capabilities:

- Average molecular weight per SEC/GPC and/or MALDI-TOF
- Polydispersity (PDI) per SEC/GPC
- Assay and purity determined per NMR and/or HPLC (CAD, ELSD)
- Diol content (for substituted PEGs) per HPLC (CAD, ELSD)
- GC for residual solvents
- X-Ray Powder Diffraction (XRPD)
- Thermal: DSC, TGA, TG-IR, bomb calorimetry

Example of a highly pure mPEG with a PDI of 1.03



This information and all further technical advice are based on our present knowledge and experience. However, it implies no liability or other legal responsibility on our part, including with regard to existing third-party intellectual property rights, especially patent rights. In particular, no warranty, whether expressed or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments. The customer is not released from the obligation to conduct careful inspection and testing of incoming goods. Performance of the product described herein should be verified by testing, which should be carried out only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is neither a recommendation, nor does it imply that similar products could not be used.

Evonik Operations GmbH

Health Care Business Line

healthcare@evonik.com www.evonik.com/healthcare

